Anhui Fengyuan Pharmaceutical Co Ltd
Anhui Fengyuan Pharmaceutical Co., Ltd. researches and develops, produces, and sells medicines in China. The company also exports its products. Anhui Fengyuan Pharmaceutical Co., Ltd. was incorporated in 1997 and is based in Hefei, China.
Anhui Fengyuan Pharmaceutical Co Ltd (000153) - Net Assets
Latest net assets as of September 2025: CN¥2.13 Billion CNY
Based on the latest financial reports, Anhui Fengyuan Pharmaceutical Co Ltd (000153) has net assets worth CN¥2.13 Billion CNY as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥4.97 Billion) and total liabilities (CN¥2.84 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥2.13 Billion |
| % of Total Assets | 42.79% |
| Annual Growth Rate | 17.89% |
| 5-Year Change | 41.29% |
| 10-Year Change | 72.76% |
| Growth Volatility | 169.92 |
Anhui Fengyuan Pharmaceutical Co Ltd - Net Assets Trend (1997–2024)
This chart illustrates how Anhui Fengyuan Pharmaceutical Co Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Anhui Fengyuan Pharmaceutical Co Ltd (1997–2024)
The table below shows the annual net assets of Anhui Fengyuan Pharmaceutical Co Ltd from 1997 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥2.05 Billion | +6.62% |
| 2023-12-31 | CN¥1.92 Billion | +9.35% |
| 2022-12-31 | CN¥1.75 Billion | +12.65% |
| 2021-12-31 | CN¥1.56 Billion | +7.58% |
| 2020-12-31 | CN¥1.45 Billion | +9.11% |
| 2019-12-31 | CN¥1.33 Billion | +2.74% |
| 2018-12-31 | CN¥1.29 Billion | +5.84% |
| 2017-12-31 | CN¥1.22 Billion | +5.87% |
| 2016-12-31 | CN¥1.15 Billion | -2.66% |
| 2015-12-31 | CN¥1.18 Billion | +3.25% |
| 2014-12-31 | CN¥1.15 Billion | +8.79% |
| 2013-12-31 | CN¥1.05 Billion | +36.04% |
| 2012-12-31 | CN¥775.01 Million | +1.28% |
| 2011-12-31 | CN¥765.24 Million | +1.52% |
| 2010-12-31 | CN¥753.81 Million | +11.07% |
| 2009-12-31 | CN¥678.70 Million | +3.76% |
| 2008-12-31 | CN¥654.09 Million | +2.38% |
| 2007-12-31 | CN¥638.89 Million | +2.97% |
| 2006-12-31 | CN¥620.49 Million | +3.49% |
| 2005-12-31 | CN¥599.59 Million | +1.44% |
| 2004-12-31 | CN¥591.07 Million | +2.62% |
| 2003-12-31 | CN¥576.00 Million | +2.70% |
| 2002-12-31 | CN¥560.87 Million | +4.61% |
| 2001-12-31 | CN¥536.15 Million | +0.69% |
| 2000-12-31 | CN¥532.50 Million | +905.06% |
| 1999-12-31 | CN¥52.98 Million | +19.47% |
| 1998-12-31 | CN¥44.35 Million | +84.56% |
| 1997-12-31 | CN¥24.03 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Anhui Fengyuan Pharmaceutical Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 41196.2% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥990.07 Million | 49.02% |
| Common Stock | CN¥464.77 Million | 23.01% |
| Other Comprehensive Income | CN¥145.31 Million | 7.20% |
| Other Components | CN¥419.41 Million | 20.77% |
| Total Equity | CN¥2.02 Billion | 100.00% |
Anhui Fengyuan Pharmaceutical Co Ltd Competitors by Market Cap
The table below lists competitors of Anhui Fengyuan Pharmaceutical Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Alvotech SDB
ST:ALVO-SDB
|
$320.61 Million |
|
Ooma Inc
NYSE:OOMA
|
$320.81 Million |
|
MayAir Technology (China) Co. Ltd. A
SHG:688376
|
$320.98 Million |
|
Cosmecca Korea Co. Ltd
KQ:241710
|
$321.00 Million |
|
Nanjing Huamai Tech Co Ltd
SHG:603042
|
$320.52 Million |
|
Deutsche Beteiligungs AG
XETRA:DBAN
|
$320.52 Million |
|
Studio Dragon Corporation
KQ:253450
|
$320.51 Million |
|
Shanghai HiTech Control System
SHE:002184
|
$320.48 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Anhui Fengyuan Pharmaceutical Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 1,889,409,585 to 2,019,573,061, a change of 130,163,476 (6.9%).
- Net income of 160,834,825 contributed positively to equity growth.
- Dividend payments of 72,171,160 reduced retained earnings.
- Share repurchases of 177,127 reduced equity.
- Other comprehensive income increased equity by 145,311,301.
- Other factors decreased equity by 103,634,363.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥160.83 Million | +7.96% |
| Dividends Paid | CN¥72.17 Million | -3.57% |
| Share Repurchases | CN¥177.13K | -0.01% |
| Other Comprehensive Income | CN¥145.31 Million | +7.2% |
| Other Changes | CN¥-103.63 Million | -5.13% |
| Total Change | CN¥- | 6.89% |
Book Value vs Market Value Analysis
This analysis compares Anhui Fengyuan Pharmaceutical Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.51x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 77.14x to 1.51x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1997-12-31 | CN¥0.09 | CN¥6.58 | x |
| 1998-12-31 | CN¥0.15 | CN¥6.58 | x |
| 1999-12-31 | CN¥0.18 | CN¥6.58 | x |
| 2000-12-31 | CN¥1.89 | CN¥6.58 | x |
| 2001-12-31 | CN¥1.90 | CN¥6.58 | x |
| 2002-12-31 | CN¥3.75 | CN¥6.58 | x |
| 2003-12-31 | CN¥3.85 | CN¥6.58 | x |
| 2004-12-31 | CN¥3.91 | CN¥6.58 | x |
| 2005-12-31 | CN¥2.11 | CN¥6.58 | x |
| 2006-12-31 | CN¥2.29 | CN¥6.58 | x |
| 2007-12-31 | CN¥2.44 | CN¥6.58 | x |
| 2008-12-31 | CN¥2.28 | CN¥6.58 | x |
| 2009-12-31 | CN¥2.63 | CN¥6.58 | x |
| 2010-12-31 | CN¥2.74 | CN¥6.58 | x |
| 2011-12-31 | CN¥2.78 | CN¥6.58 | x |
| 2012-12-31 | CN¥2.82 | CN¥6.58 | x |
| 2013-12-31 | CN¥3.39 | CN¥6.58 | x |
| 2014-12-31 | CN¥3.56 | CN¥6.58 | x |
| 2015-12-31 | CN¥3.69 | CN¥6.58 | x |
| 2016-12-31 | CN¥3.69 | CN¥6.58 | x |
| 2017-12-31 | CN¥3.91 | CN¥6.58 | x |
| 2018-12-31 | CN¥4.06 | CN¥6.58 | x |
| 2019-12-31 | CN¥4.24 | CN¥6.58 | x |
| 2020-12-31 | CN¥4.53 | CN¥6.58 | x |
| 2021-12-31 | CN¥4.90 | CN¥6.58 | x |
| 2022-12-31 | CN¥5.45 | CN¥6.58 | x |
| 2023-12-31 | CN¥5.69 | CN¥6.58 | x |
| 2024-12-31 | CN¥4.35 | CN¥6.58 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Anhui Fengyuan Pharmaceutical Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 7.96%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 3.75%
- • Asset Turnover: 0.91x
- • Equity Multiplier: 2.33x
- Recent ROE (7.96%) is above the historical average (5.84%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1997 | 18.61% | 10.13% | 0.75x | 2.45x | CN¥2.07 Million |
| 1998 | 17.78% | 15.50% | 0.45x | 2.55x | CN¥3.37 Million |
| 1999 | 16.64% | 15.09% | 0.42x | 2.59x | CN¥3.44 Million |
| 2000 | 4.94% | 23.01% | 0.18x | 1.19x | CN¥-26.87 Million |
| 2001 | 4.63% | 15.56% | 0.22x | 1.33x | CN¥-28.74 Million |
| 2002 | 4.60% | 16.35% | 0.23x | 1.22x | CN¥-30.26 Million |
| 2003 | 3.15% | 10.12% | 0.24x | 1.28x | CN¥-39.48 Million |
| 2004 | 1.64% | 3.42% | 0.31x | 1.53x | CN¥-48.97 Million |
| 2005 | 1.52% | 2.05% | 0.40x | 1.84x | CN¥-50.44 Million |
| 2006 | 3.58% | 4.22% | 0.49x | 1.73x | CN¥-39.53 Million |
| 2007 | 0.89% | 0.80% | 0.65x | 1.72x | CN¥-57.71 Million |
| 2008 | 2.19% | 1.62% | 0.75x | 1.80x | CN¥-50.58 Million |
| 2009 | 3.42% | 2.41% | 0.79x | 1.80x | CN¥-44.16 Million |
| 2010 | 5.83% | 3.88% | 0.84x | 1.79x | CN¥-29.73 Million |
| 2011 | 1.37% | 0.65% | 1.15x | 1.82x | CN¥-62.43 Million |
| 2012 | 2.59% | 1.15% | 1.14x | 1.98x | CN¥-54.40 Million |
| 2013 | 2.70% | 1.79% | 0.77x | 1.95x | CN¥-74.01 Million |
| 2014 | 3.68% | 2.41% | 0.76x | 2.01x | CN¥-70.25 Million |
| 2015 | 2.81% | 2.08% | 0.67x | 2.00x | CN¥-82.68 Million |
| 2016 | 3.98% | 2.25% | 0.82x | 2.16x | CN¥-69.44 Million |
| 2017 | 5.35% | 2.53% | 0.93x | 2.27x | CN¥-56.70 Million |
| 2018 | 4.73% | 2.02% | 1.00x | 2.33x | CN¥-67.94 Million |
| 2019 | 6.11% | 2.50% | 0.91x | 2.69x | CN¥-51.51 Million |
| 2020 | 7.34% | 3.12% | 0.91x | 2.57x | CN¥-37.63 Million |
| 2021 | 8.05% | 3.51% | 0.92x | 2.50x | CN¥-29.83 Million |
| 2022 | 8.93% | 3.86% | 0.90x | 2.59x | CN¥-18.42 Million |
| 2023 | 8.43% | 3.73% | 0.97x | 2.32x | CN¥-29.66 Million |
| 2024 | 7.96% | 3.75% | 0.91x | 2.33x | CN¥-41.12 Million |
Industry Comparison
This section compares Anhui Fengyuan Pharmaceutical Co Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $2,228,406,931
- Average return on equity (ROE) among peers: -0.55%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Anhui Fengyuan Pharmaceutical Co Ltd (000153) | CN¥2.13 Billion | 18.61% | 1.34x | $320.56 Million |
| Shenzhen Neptunus Bioengineering Co Ltd (000078) | $6.47 Billion | 9.88% | 3.77x | $616.08 Million |
| Shan Dong Dong-E E-Jiao Co Ltd (000423) | $10.33 Billion | 15.07% | 0.27x | $3.03 Billion |
| Wedge Industrial Co Ltd (000534) | $298.72 Million | 1.96% | 0.38x | $1.77 Billion |
| Yunnan Baiyao Group Co Ltd (000538) | $35.11 Million | 18.13% | 0.80x | $5.62 Billion |
| Hainan Haiyao Co Ltd (000566) | $353.98 Million | -9.58% | 0.80x | $702.18 Million |
| Tus Pharmaceutical Group Co Ltd (000590) | $269.51 Million | -61.02% | 1.05x | $317.08 Million |
| Northeast Pharmaceutical Group Co Ltd (000597) | $927.49 Million | 2.65% | 1.38x | $425.60 Million |
| Jilin Aodong Pharmaceutical Group Co Ltd (000623) | $1.11 Billion | 7.32% | 0.29x | $2.05 Billion |
| Renhe Pharmacy Co Ltd (000650) | $261.49 Million | 10.60% | 0.82x | $777.45 Million |